Oncology
12 drugs are in development for Multiple Myeloma.
- Companies
- 11
- Clinical trials
- 181
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Multiple Myeloma pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| abecma | 2seventy bio, Inc. (TSVT) |
Phase 3(1)
| Drug | Company |
|---|---|
| imetelstat | GERON CORP (GERN) |
Phase 2(1)
| Drug | Company |
|---|---|
| elotuzumab | BRISTOL MYERS SQUIBB CO (BMY) |
Phase 1(7)
Preclinical(1)
| Drug | Company |
|---|---|
| kb-9558 | Kronos Bio, Inc. (KRON) |
Phase 4(1)
| Drug | Company |
|---|---|
| elranatamab | PFIZER INC (PFE) |
About this indication
Multiple Myeloma context
Oncology·MeSH: Multiple Myeloma (D009101)
Also known as: Disease, Kahler, Multiple Myelomas, Myeloma Multiple, Myeloma, Plasma Cell, Myeloma-Multiples, Myelomas, Plasma-Cell, Myelomatoses, Myelomatosis
Prevalence
17.0 / 100K
Incidence
7.0 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Multiple Myeloma?
BioSniper tracks 12 drugs in development for Multiple Myeloma across 11 companies.
How many clinical trials target Multiple Myeloma?
There are 181 clinical trials targeting Multiple Myeloma tracked by BioSniper.
What is the prevalence of Multiple Myeloma?
The estimated prevalence of Multiple Myeloma is approximately 17.0 per 100,000 population.